Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2020

View Archived Issues

Fast route from fibroblasts to photoreceptors

Eating proinflammatory IgG helps prevent liver failure

Sinovac initiates phase I study of its vaccine candidate against COVID-19

FAM13A variants lead to changes in adipocyte differentiation regulation and body fat distribution

A paracrine interaction between breast cancer cells and MAFs promotes metastatic progression

CAR macrophages with directed antitumor phagocytic activity for cancer immunotherapy

Anixa and OntoChem collaborate to develop novel antiviral therapies against COVID-19

Pivotal CheckMate-743 trial of Opdivo plus Yervoy in MPM meets primary endpoint

Phase III CheckMate-9ER study of Opdivo and Cabometyx in RCC meets primary endpoint

FDA clears IND to initiate phase I/II study of PRGN-2009

Long noncoding RNA has sex-specific role in depression

Alexion to initiate global phase III study of Ultomiris in severe COVID-19

Promising topline data for Xeris' novel intramuscular injection formulation of diazepam

First COVID-19 patient treated under emergency use IND with Stemedica's itMSCs

BCH-070, a novel antiparasitic candidate against multidrug-resistant malaria

RAPT Therapeutics patents USP7 inhibitors

Arbidol shows superior efficacy compared to lopinavir/ritonavir in treating COVID-19

Regenacy Pharmaceuticals discloses HDAC1 and/or HDAC2 inhibitors

Genzyme identifies new GALC inhibitors

Cardurion Pharmaceuticals synthesizes new CAMK2 inhibitors

New nitric oxide production inhibitors presented by FronThera US Pharmaceuticals

Nucorion begins first-in-human study of NCO-48 fumarate for hepatitis B

IMDC recommends continuation of phase III trial of eryaspase in advanced pancreatic cancer

Cara reports topline data from KALM-2 trial of Korsuva in hemodialysis patients with pruritus

Phase III VANISH-306 study of oral ibrexafungerp in VVC meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...